相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2-methoxyestradiol inhibits melanoma cell growth by activating adaptive immunity
Weitian Hua et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2022)
Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer
Iris C. Salaroglio et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
Tiziana Vavala et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma
Bongkum Choi et al.
CANCER LETTERS (2020)
Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications
Tanner Smida et al.
FRONTIERS IN ONCOLOGY (2020)
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
A. Capasso et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports
Toshiaki Takahashi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Urania Dafni et al.
LUNG CANCER (2019)
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?
Stefano Frega et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer
Chengdi Wang et al.
CANCER MEDICINE (2019)
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
E. J. Aguilar et al.
ANNALS OF ONCOLOGY (2019)
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
Diana C. Marquez-Garban et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers A Systematic Review and Meta-analysis
Christopher J. D. Wallis et al.
JAMA ONCOLOGY (2019)
The Role of the Estrogen Pathway in the Tumor Microenvironment
Natalie J. Rothenberger et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti et al.
LANCET ONCOLOGY (2018)
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer
Edward B. Garon et al.
LUNG CANCER (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Influence of estrogen in non-small cell lung cancer and its clinical implications
Vianey Rodriguez-Lara et al.
JOURNAL OF THORACIC DISEASE (2018)
Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism
Camila M. Lopes-Ramos et al.
CANCER RESEARCH (2018)
Sex Differences in Cancer Driver Genes and Biomarkers
Constance H. Li et al.
CANCER RESEARCH (2018)
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
Antonino Grassadonia et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer
Brant A. Inman et al.
CLINICAL CANCER RESEARCH (2017)
Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells
Nikolaos Svoronos et al.
CANCER DISCOVERY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Increased levels of enzymes involved in local estradiol synthesis in chronic obstructive pulmonary disease
G. F. J. Konings et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2017)
Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
Kenichi Suda et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat et al.
CANCER RESEARCH (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex
Rossana Berardi et al.
ONCOTARGET (2016)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Prognostic value of estrogen receptors mRNA expression in non-small cell lung cancer: A systematic review and meta-analysis
Wentao Li et al.
STEROIDS (2015)
Role of estrogen in lung cancer based on the estrogen receptor-epithelial mesenchymal transduction signaling pathways
Xiao-zhen Zhao et al.
ONCOTARGETS AND THERAPY (2015)
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
Zhijie Wang et al.
SCIENTIFIC REPORTS (2015)
Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor a signalling and results in tamoxifen insensitive proliferation
Marja Moerkens et al.
BMC CANCER (2014)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes
Ivana Campia et al.
BIOCHEMICAL JOURNAL (2012)
Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer
Jill M. Siegfried et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer
Nadiyah Kazmi et al.
LUNG CANCER MANAGEMENT (2012)
Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age
Z. Desta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy
Luisella Righi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Aromatase expression predicts survival in women with early-stage non-small cell lung cancer
Vei Mah et al.
CANCER RESEARCH (2007)
Estrogen receptor-α phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression
Gregory E. Weitsman et al.
CANCER RESEARCH (2006)
Estrogen receptor α and β are prognostic factors in non-small cell lung cancer
H Kawai et al.
CLINICAL CANCER RESEARCH (2005)
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects
LP Stabile et al.
CANCER RESEARCH (2005)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer
JFR Robertson et al.
CLINICAL PHARMACOKINETICS (2004)
分享论文
